Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
RMD Open. 2025;11:e005026. doi: 10.1136/rmdopen-2024-005026.
Mease et al. found that bimekizumab demonstrated a favourable long-term safety profile in patients with axSpA and PsA.